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Ischemia-reperfusion injury is a composite of damage accumulated during reduced perfusion of an organ or tissue and the
additional insult sustained during reperfusion. Such injury occurs in a wide variety of clinically important syndromes, such as
ischemicheartdiseaseandstroke,whichareresponsibleforahighdegreeofmorbidityandmortalityworldwide.Basicresearchhas
identiﬁed a number of interventions that stimulate innate resistance of tissues to ischemia-reperfusion injury. Here, we summarise
the experimental and clinical trial data underpinning one of these “conditioning” strategies, the phenomenon of remote ischemic
preconditioning.
1.Introduction
Ischemia-reperfusion injury underpins the damage of
myocardial infarction, stroke, and other conditions compli-
cated by interruption of the blood supply to tissues. Strate-
gies to limit the duration of ischemia have achieved sub-
stantial health gains in myocardial infarction and, to a lesser
degree, stroke. However door-to-needle times have probably
reached the minimum that is possible in many health-care
delivery systems, so further reduction in morbidity and
mortality from IR injury will require strategies to increase
tissue tolerance to ischemia or reduce damage that occurs on
reperfusion.Onesuchapproachisischemicpreconditioning,
and its variant remote ischemic preconditioning, the subject
of this paper.
2. Typesof Ischemic Preconditioning
Ischemic preconditioning (IPC) describes the phenomenon
whereby transient, brief periods of ischemia confer protec-
tion against a subsequent prolonged and injurious period
of ischemia. There are a number of ways in which pre-
conditioning can be induced. Local preconditioning occurs
when the preconditioning stimulus is applied to the same
organ or tissue that will subsequently sustain the ischemic
injury. Remote ischemic preconditioning refers to a stimulus
applied to a distant organ or tissue, which then protects
against index ischemia. For example, the preconditioning
stimulus might be suprasystolic blood pressure inﬂations
on an arm or leg, which then confer myocardial protection
against subsequent ischemia. Postconditioning occurs when
there is staged reperfusion, for example, in the setting of
balloon angioplasty. Its variant perconditioning occurs when
the conditioning stimulus is applied during ischemia.
3. Ischemic Preconditioning
Ischemic preconditioning was ﬁrst described in 1986, when
Murry et al. demonstrated that in the dog, brief episodes
of ischemia (4 cycles of 5-minute occlusion followed by
reperfusion) of the circumﬂex artery reduced the extent of
infarction induced by subsequent prolonged occlusion of
that vessel [1]. This protection expired after a few hours, but
subsequent studies indicated that it recovered approximately
24 hours later, this second phase of protection lasting for up
to a further 72 hours [2–4]. Despite the length of time that
has elapsed since the discovery of IPC, detailed exposition
of its mechanism, and evidence that the biological processes
operate in humans, IPC has never progressed to detailed
clinical investigation. This was largely due to the logistics
of inducing preconditioning ischemia in vital organs (such
as the heart or brain) in advance of a more prolonged2 Cardiology Research and Practice
insult (e.g., that would lead to myocardial infarction or
stroke).
4. Remote Ischemic Preconditioning
A major breakthrough in clinical applicability of precondi-
tioning protection came with the discovery that ischemic
preconditioning also had a systemic protective phenotype.
This facet, termed remote ischemic preconditioning (RIPC),
resulted in protection from ischemia-reperfusion injury at
sites remote from those undergoing the preconditioning
stimulus. This was ﬁrst described in the setting of exper-
imental coronary artery occlusion, where preconditioning
one vascular territory of the heart eﬀected protection in
adjacent tissue that had not undergone any preconditioning
ischemia [5]. Interorgan protection was conﬁrmed by the
observationthatpreconditioningstimuliappliedtothesmall
bowel [6] or kidney [7] reduced infarct size in the heart.
As was the case for IPC, further studies established that the
time course of protection caused by RIPC was also biphasic.
The demonstration that RIPC could be activated merely via
brief periods of limb ischemia simpliﬁed the logistics of
inducing ischemic preconditioning in animals and humans
[8]. Moreover, RIPC activated by limb ischemia protected
from experimental IR injury in humans. Together these
observations framed the conditions that have led to a large
number of clinical trials of RIPC in patients.
5. Mechanisms of Tissue Protection of
IPCandRIPC
During ischemia, anaerobic metabolism predominates and
ATP production decreases. There is insuﬃcient available
energy to maintain cell membrane pump activity, antioxi-
dant defences, pH and calcium homeostasis, and mitochon-
drial integrity. These and other consequences of ischemia
inevitably lead to cell death, unless blood ﬂow is restored.
Though reperfusion with oxygenated blood is essential for
any tissue salvage, the sudden inﬂux of oxygen leads to the
formationofreactiveoxygenspecies.Akeyeventincelldeath
ismitochondrialpermeabilitytransition,aphenomenonthat
occurs when the mitochondrial permeability transition pore
(mPTP) becomes permeable to molecules of 1500kDa or
smaller. This leads to a rapid inﬂux of small molecules,
mitochondrial swelling, and subsequent cell death [8].
IPC activates three main salutatory pathways, the cyclic
guanosine monophosphate/cGMP-dependent protein kinase
(cGMP/PKG) pathway [9], the reperfusion injury salvage
kinase (RISK) pathway [10], and the survivor activating
factor enhancement (SAFE) pathway [11] .T h e r ei sad e g r e e
of overlap, in particular where the pathways converge on
the mitochondrion [12]. Here, the potassium-dependent
ATP (KATP) channel is activated with evidence that this
leads to closure of the mPTP. IPC also initiates a complex
genomic and proteomic response that underpins the late
phase of protection. This includes antiapoptotic and anti-
inﬂammatory gene transcription, likely to be responsible for
the second window of protection [13, 14].
Triggers in the initial cascade recruit early mediators
(such as protein kinase C (PKC), tyrosine kinase, phos-
phatidylinositol 3-kinases (PI3K), protein kinase B (PKB
or Akt) [15], mitogen-activated protein kinases (MAP1/2
or MEK1/2), extracellular signal-regulated kinases (Erk1/2),
and janus kinase (JAK)), which activate transcription factors
(such as signal transducer and activator of transcription pro-
teins (STAT1/3), nuclear factor kappa-light-chain-enhancer
of activated B cells (NFκB), activator-protein-1 (AP-1),
nuclear factor-like 2 (Nrf2), and hypoxia-inducible-factor-
1α (HIF-1α)). Later phase protection requires synthesis of
inducible nitric oxide synthase (iNOS), heat shock proteins
(HSPs), or cyclooxygenase-2 (COX-2). These then act locally
via the mPTP or KATP channels to induce a state of
cardioprotection [16].
6. Mechanismof the Systemic
Spread of Protection
Evidence for involvement of a humoral factor in mediating
systemic spread is supported by the observation that protec-
tion can be transferred by the transfusion of serum from a
rabbit that has undergone ischemic preconditioning to one
which has not [17, 18]. This factor appears to be heat stable
and has been shown to be dialysable and of less than 15kD
[19, 20]. In some studies it is blocked by opioid antagonists,
including naloxone [21, 22].
Neurogenic mechanisms have also been explored using
autonomic ganglionic blockade. In a rat myocardial infarc-
tion model hexamethonium abolished protection by RIPC
achieved by mesenteric artery occlusion (MAO) but had
no eﬀect on myocardial IPC. Cardioprotection was absent
when MAO was sustained throughout the study, indicating
that reperfusion in the small intestine was essential to acti-
vate the neurogenic pathway [6]. The autonomic ganglion
blocker trimethaphan has also been shown to inhibit remote
ischemic preconditioning in a human model [23]. In the
rabbit, sympathetic nerve activity increases when RIPC is
induced using renal ischemia, consistent with a particular
role for the adrenergic component of the autonomic system
in this species [24].
Noradrenaline has been implicated; however, studies
are conﬂicting about its potential role. Administration of
noradrenaline has been shown to induce preconditioning in
animal models [25]; however, studies diﬀer as to whether
alpha-adrenoceptor blockers such as prazosin inhibit pre-
conditioning [25, 26]. Noradrenaline levels were not seen
to be increased in the serum of preconditioned rabbits,
which when transfused conferred preconditioning, leading
to doubts about a role in the transfer of protection [18].
Sensory nerves have also been implicated in spread of
protection. Intramesenteric bradykinin has been demon-
strated in animal models to stimulate local sensory nerves,
resulting in RIPC-like protection that is abolished by
hexamethonium [27]. This suggests a pathway involving
sensory nerves and the autonomic nervous system. However,
a recent human healthy volunteer study demonstrated that
the bradykinin-2 inhibitor HOE-140 had no eﬀect on RIPCCardiology Research and Practice 3
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Figure 1: proposed mechanisms of remote ischemic preconditioning.
[28], so as ever mechanisms might be diﬀerent in humans.
Calcitonin-gene-relatedpeptide(CGRP),aneurotransmitter
in capsaicin-sensitive sensory nerves (CSSNs), has also been
implicated [29, 30]. CGRP has been reported to increase
systemically after RIPC, and pretreatment with capsaicin (to
deplete CSSN) blocks RIPC [31].
The nonselective adenosine antagonist 8-(p-sulfophe-
nyl)theophylline (8-SPT) has been shown in a rabbit [24,
32, 33]a n dr a t[ 34] model to abolish the protective
eﬀectsofremoteischemicpreconditioning.Adenosinemight
therefore be one step in a complex pathway, though not itself
the circulating factor.
The humoral and neuronal pathways may work in series
to spread protection systemically. In the rat, release of
the dialysable humoral factor is prevented by hindlimb
denervation [35].
Themechanismsoftissueprotectionandsystemicspread
have been summarised in Figure 1.
7.Mechanismof IPCandRIPCinHumans
The development of a vascular model of human IR injury
has facilitated the investigation of the mechanism of IPC
and RIPC. In this model the arm is made ischemic for
20 minutes, and this safely induces a transient period of
endothelial dysfunction in the conduit and resistance vessels.
Endothelial assessment has been made using ultrasound
of conduit vessels to measure ﬂow-mediated dilatation
or forearm plethysmography to characterize the response
of resistance vessels to endothelium-dependent agonists.
In this model, vascular smooth muscle function is pre-
served. Endothelial dysfunction is largely prevented if the
ischaemic period is preceded by brief, repeated periods
of ischaemia ipsilaterally (IPC) [36] and contralaterally
(RIPC) [37, 38], with two phases of protection [38].
Administration of KATP channel blockers prevents IPC in
healthy volunteers, and IPC is mimicked by KATP channel
opening drugs [39, 40]. A number of studies suggest
that IR injury is dependent on increased oxidative stress
[41, 42], making it possible that IPC and RIPC stimulate
antioxidant defences [43]. Regarding the systemic spread
of protection, ganglionic blockade inhibits both phases of
RIPC [6, 38], though as yet it is unclear which com-
ponent of the autonomic system is responsible. Dialysate
of human plasma from volunteers who have undergone
RIPC reduces IR injury in vitro in an opiate-dependent
manner, and this supports activation of opiate pathways
in humans [20]. However, the relative contributions of4 Cardiology Research and Practice
the neuronal and humoral pathways remain to be deter-
mined.
8.ClinicalTrials:CurrentStatus
Although initial clinical trials in this area focussed on the
application of remote ischemic preconditioning in ischemic
cardiac disease, interest has broadened to other areas of
potential clinical beneﬁt, including acute kidney injury,
stroke, and transplantation.
A table summarising clinical trials in remote ischemic
preconditioning to date is shown (Table 1).
8.1.CardiacSurgery. Theﬁrstclinicaltrialofremoteischem-
ic preconditioning was in 2000, when 8 patients undergoing
coronary artery bypass grafting (CABG) were randomised
to receive either ischemic preconditioning (forearm cuﬀ
inﬂated to 300mmHg for 2 cycles of 3 minutes) or control.
Thestudydemonstratedanincreaseinlactatedehydrogenase
(LDH) in the preconditioned group, which was attributed
to an ability to maintain anaerobic metabolism in precon-
ditioned cells [44].
Following this, a randomised controlled trial of RIPC
in the setting of pediatric surgery (37 patients) for con-
genital cardiac defects demonstrated that 4 cycles of 5
minutes of lower limb ischemia prior to surgery were
eﬀective in reducing troponin levels, postoperative inotropic
requirements, and airways resistance at 6 hours [45]. A
study of arm preconditioning in simple congenital cardiac
defects (ventricular septal defect repair) demonstrated an
improvement in lung compliance and a decrease in cardiac
enzymes (LDH, CK, and troponin I) and cytokines (IL-6,
IL-8, IL-10, and TNF-α) in the preconditioned group. In
this study, those randomised to the preconditioning group
received preconditioning at 24 hours and 1 hour before
surgery, to utilise both early and late phases of protection
[46].
Subsequently in 2007, Hausenloy et al. demonstrated
a reduction in troponin T levels in patients randomised
to receive ischemic preconditioning (3 cycles of 5-minute
forearmcuﬀinﬂationto200mmHgafterinductionofanaes-
thesia) prior to coronary artery bypass grafting [47]. In both
these trials, the patients underwent cross-clamp ﬁbrillation;
however, Venugopal et al., in 2009, also demonstrated a
reduction in troponin T following remote ischemic precon-
ditioning in patients undergoing cold blood cardioplegia
[48].
However, in 2010, Rahman et al. published a larger
single-centre double-blind randomised controlled trial in
which 162 patients undergoing CABG were randomised
to receive either 3 × 5-minute cycles of upper limb cuﬀ
inﬂation to 200mmHg (separated by 5-minute reperfusion)
or placebo (in which the cuﬀ was inﬂated on a “dummy
arm”). In this study there was no diﬀerence in troponin
release between the 2 groups [49]. There was also no
diﬀerence in cardiac performance, inotrope requirement,
echocardiographic function, arrhythmia protection, or renal
and lung outcomes.
The RICO trial (the Eﬀect of Remote Ischemic Con-
ditioning on Atrial Fibrillation and Outcome) is ongoing
to examine the eﬀects of remote ischemic preconditioning,
remote ischemic postconditioning, or remote ischemic pre-
and postconditioning on the development of atrial ﬁbrilla-
tion on holter monitor within 72 hours after coronary artery
bypass grafting [50]. This will help to deﬁne if there is any
clinical beneﬁt of combining preconditioning strategies.
A current multicenter double-blind randomised con-
trolled trial, “Eﬀect of Remote Ischemic Preconditioning on
Clinical Outcomes in Patients Undergoing Coronary Artery
Bypass Graft Surgery” (ERICCA), is currently underway to
investigate whether RIPC improves one-year cardiovascular
outcomes and reduces acute kidney injury (AKI) in the
setting of cold-blood cardioplegia CABG. This trial aims to
recruit 1610 patients, randomised to either RIPC or sham-
RIPC.
8.2. Percutaneous Coronary Intervention (PCI) for Acute
Myocardial Infarction (AMI). In 2006, Iliodromitis et al.
investigated whether RIPC by 3 cycles of 5-minute ischemia
applied to both arms would attenuate the inﬂammatory
response in elective single vessel PCI with coronary stenting.
They in fact demonstrated an increase in CK-MB, troponin
I, and CRP in the preconditioned group and postulated that
RIPC increased the inﬂammatory response [51].
Subsequently, Hoole et al., in 2009, in a study of 242
patients undergoing elective PCI demonstrated that RIPC
(3 cycles of 5-minute forearm cuﬀ inﬂation to 200mmHg)
prior to PCI attenuated procedure-related cardiac troponin
I (cTnI) release [52]. Diabetics and hypertensives were
included and also beneﬁted. However, in a separate study the
same group showed that there was no beneﬁcial eﬀect on left
ventricular dysfunction during coronary balloon occlusion
in single vessel coronary disease [53].
Also of note, Bøtker et al. demonstrated the potential
for prehospital use of remote ischemic perconditioning in the
setting of AMI (4 cycles of 5-minute forearm cuﬀ inﬂation
and deﬂation, delivered in the ambulance). In a trial of 333
patients, they demonstrated an improvement in myocardial
salvage index (%) at 20 days after primary PCI in the group
randomised to receive preconditioning [54]. In a substudy
of the same patients, remote ischemic conditioning delivered
before hospital seemed to result in modest improvement
in LV function in high-risk patients prone to develop large
myocardial infarcts [55].
8.3. Vascular Surgery. In open abdominal aortic aneurysm
(AAA) repair, 82 patients were randomised to receive either
RIPC (two cycles of intermittent cross-clamping of the com-
mon iliac artery with 10-minute ischemia followed by 10-
minute reperfusion) or none. RIPC reduced the absolute risk
of myocardial injury, myocardial infarction, and renal injury
[56]. Another study in the same clinical scenario, in which
51 patients were randomised to sequential common iliac
artery cross-clamping as the conditioning stimulus or none,
did not demonstrate any improvement in renal outcome
indices (urinary retinol binding protein (RBP) and albu-
min:creatinineratio(ACR))[57].Thesamegr oup ,ho wev er ,Cardiology Research and Practice 5
Table 1: Clinical trials to date in remote ischemic preconditioning.
Year n Author Clinical setting Conditioning protocol Results
2000 8 G¨ unyaydin Coronary artery bypass grafting
(CABG) Arm 2 × 3min
↑Lactate dehydrogenase (LDH) in
preconditioned group
2005 12 Chan
Clipping of cerebral aneurysm
following subarachnoid
haemorrhage
Proximal artery 2min catheter
occlusion, 30min reperfusion
↓tissue hypoxia (slower decline in
pO2 and pH)
2006 41 Iliodromitis
Elective single vessel percutaneous
coronary intervention (PCI) and
stenting
Both arms 3 × 5min Increased troponin I, CK-MB, and
C-reactive protein (CRP)
2006 37 Cheung Paediatric surgery for congenital
cardiac defects Leg 4 × 5min
↓troponin T, ↓post-op inotrope
requirements, ↓airway resistance
2007 82 Ali Elective open abdominal aortic
aneurysm repair
Internal iliac cross-clamp 2 ×
10min
↓absolute risk of myocardial
injury/infarction (troponin I) and
renal injury (creatinine)
2007 57 Hausenloy Elective CABG Arm 3 × 5min ↓troponin T
2008 165 Faries Balloon occlusion during carotid
angioplasty and stenting
Temporary balloon occlusion of
ICA
Decreased Glasgow Coma Score
(GCS) seen on initial balloon
inﬂation not observed when blood
reinﬂated
2009 45 Venugopal CABG (cold-blood cardioplegia)
+/− valve replacement Arm 3 × 5min ↓troponin T
2009 242 Hoole Elective PCI Arm 3 × 5min
↓troponin I, reduces ischaemic pain
during PCI
2009 42 Hoole Elective PCI for single vessel
coronary artery disease Arm 3 × 5min




2009 40 Walsh Endovascular AAA repair Both legs 10min ischaemia
Reduced urinary retinol binding
protein and albumin:creatinine
ratio
2010 70 Walsh Carotid endarterectomy Both legs 10min ischaemia
Fewer saccadic latency
deteriorations (did not reach
statistical signiﬁcance)
2010 78 Venugopal CABG Arm 3 × 5min
Post hoc analysis of 2 previous
studies. Decreased Acute Kidney
Injury (AKI) on Acute Kidney
Injury Network (AKIN) criteria
2010 162 Rahman CABG (on-pump) Arm 3 × 5min





2010 120 Wagner CABG with cold crystalloid
cardioplegia Arm 3 × 5min
↓troponin I; tramadol
administration increased troponin
2010 51 Walsh Open infrarenal AAA repair Sequential common iliac clamping
No diﬀerences in renal outcomes
(urinary retinol binding protein
(RBP) and albumin:creatinine
ratio (ACR))
2010 60 Wenwu Ventricular septal defect repair Arm 3 × 5min; 24h and 1h before
surgery
Reduced cytokines and cardiac
enzymes, upregulation of heat
shock protein (HSP) 70; improved
lung compliance
2010 40 Hu
Elective decompression surgery for
adult cervical spondylotic
myelopathy
Arm 3 × 5min
Reduced markers of ischaemic
neuronal injury S-100B and
neuron-speciﬁc enolase; improved
recovery rate on functional score
2011 120 Zimmerman Cardiac surgery with
cardiopulmonary bypass Leg 3 × 5min Reduced relative risk of AKI on
AKIN criteria6 Cardiology Research and Practice
Table 1: Continued.
Year n Author Clinical setting Conditioning protocol Results
2011 113 Pedersen Paediatric surgery for correction of
complex cardiac defects Leg 4 × 5min No eﬀect on development of AKI,
urine output, or urinary biomarkers
2011 76 Choi Complex valvular heart surgery
with CPB Leg 3 × 5min




Decreased CK-MB at 24 hours
2011 242 Munk Primary PCI for acute MI Arm 4 × 5min, prehospital Modest improvement in LV systolic
function (not signiﬁcant)
demonstrated lower levels of RBP and albumin:creatinine
ratio following surgery in the preconditioned group in the
setting of endovascular AAA repair (EVAR) [58].
A UK-based trial of remote ischaemic preconditioning in
the setting of elective abdominal aortic aneurysm repair is
currently underway in Bristol.
8.4. Brain and Neurological Injury. A pilot clinical trial of
70 patients undergoing carotid endarterectomy, randomised
to remote ischemic preconditioning with 10 minutes of
ischemic applied to each leg showed a numerical but not
statistical reduction in saccadic latency deteriorations (the
primary neurological outcome). There was no signiﬁcant
diﬀerence between cardiac endpoints [59].
However, in a trial in 40 adult cervical spondylotic
myelopathy patients undergoing elective decompression
surgery there was a signiﬁcant reduction in markers of
ischemic neurological injury (serum S-100B and neuron-
speciﬁc enolase) in the RIPC group. Patients randomized to
RIPCreceived3×5-minutearmcycles.Postsurgicalrecovery
at 7 days, 1, and 3 months after surgery (evaluated using a
Japanese Orthopaedic Association scale) was higher in the
preconditioned group [60].
In stroke, the “New Acute Treatment for Stroke—The
Eﬀect of Remote Perconditioning” has recently closed to
recruitment and results awaited. This trial has examined
the utility of remote ischemic preconditioning using arm
ischemia in the ambulance prior to hospital admission and
thrombolysis. The primary endpoint in this study is salvage
index, measured on diﬀusion-weighted T2 MRI.
8.5. Acute Kidney Injury (AKI). IR injury contributes to the
majority of AKI. Common causes of AKI such as sepsis,
surgery, or drugs, for example, NSAIDS, ACE inhibitors,
are all essentially wholly or in part due to ischemia-
reperfusion injury, secondary to hypotension or reduced
renal blood ﬂow. AKI is responsible for morbidity and
increasedmortalityinhospitaladmissions;however,itsonset
is often unpredictable and patients present when AKI is
already manifest. Therefore, use of RIPC to protect against
acute kidney injury has most widely been documented in the
setting of surgery. In this setting, however, the acute injury is
complex and multifactorial in nature.
Secondary analysis from two trials in elective coronary
artery bypass grafting has demonstrated a reduction in
AKI in nondiabetic patients randomised to RIPC (three 5-
minute cycles of forearm ischemia). However, the numbers
were small, there were more concomitant aortic valve
replacements in the RIPC group, the analysis was post
hoc, and, although there were more episodes of AKI in
the nonintervention group, this was all AKI stage 1. [61]
In a separate study of lower limb preconditioning in the
settingofcardiacsurgeryrequiringcardiopulmonarybypass,
AKI was reduced in the RIPC group (47% versus 20%).
All AKI was either stage 1 or 2 [62]. A recently published
trial of leg preconditioning in children undergoing surgery
for complex congenital cardiac disease found no evidence
that preconditioning protected renal function. End points
were development of acute kidney injury, initiation of
dialysis, plasma creatinine, estimated glomerular ﬁltration
rate, plasma cystatin C, plasma and urinary neutrophil
gelatinase-associated lipocalin, and urinary output [63]. A
similar study in adults again demonstrated no evidence
of beneﬁt in renal protection following complex cardiac
surgery; however, a reduction in CK-MB was observed [64].
Trials examining the eﬀects of preconditioning on AKI in
the setting of AAA surgery have been detailed above.
8.5.1. Solid Organ Transplantation. The ultimate renal IR
injury occurs in renal transplantation, and in the case of
live donor transplantation this has a predictable time of
onset. Loukogeorgakis et al. have previously demonstrated
an almost 20% improvement in eGFR (Modiﬁcation of
Diet in Renal Disease (MDRD) formula) after 2 years
in children who underwent RIPC before live donor renal
transplantation. Both donor and recipient received 3 cycles
of 5-minute forearm ischemia-reperfusion, 24 hours prior
to transplantation. This was a small randomised controlled
trial in 20 patients; however, a larger, 400-pair multicen-
tre randomised controlled trial (Renal Protection against
Ischemia Reperfusion in Transplantation (REPAIR)) is cur-
rently underway. A trial of RIPC in the setting of cadaveric
renal transplantation is being undertaken by Bøtker et al.
The RIPCOT trial (Remote Ischemic Preconditioning in
Abdominal Organ Transplantation), which utilises lower
limb remote ischemic preconditioning in the setting of
deceased donor liver, kidney, or pancreas transplantation,
andRIPCbeforeabdominalsurgerytrialinthoseundergoing
abdominal, large bowel, pancreatic, and hepatic surgery are
also currently underway.Cardiology Research and Practice 7
9. Conclusion
Remote ischemic preconditioning harnesses a powerful
innate protective mechanism against ischemic injury. The
mechanism is as yet not fully elucidated; however, it has
shown promise in clinical trials. No trial has yet been large
enough to demonstrate an eﬀect of RIPC to reduce the
incidence or impact of clinically relevant consequences of IR
injury.However,largeadequatelypoweredstudieswillreport
within the next 2-3 years. These trials will either endorse the
clinical usefulness of ischemic preconditioning or consign it
to the laboratory.
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